2,384 results on '"Avezum, A."'
Search Results
152. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study
- Author
-
O'Donnell, Martin J, Chin, Siu Lim, Rangarajan, Sumathy, Xavier, Denis, Liu, Lisheng, Zhang, Hongye, Rao-Melacini, Purnima, Zhang, Xiaohe, Pais, Prem, Agapay, Steven, Lopez-Jaramillo, Patricio, Damasceno, Albertino, Langhorne, Peter, McQueen, Matthew J, Rosengren, Annika, Dehghan, Mahshid, Hankey, Graeme J, Dans, Antonio L, Elsayed, Ahmed, Avezum, Alvaro, Mondo, Charles, Diener, Hans-Christoph, Ryglewicz, Danuta, Czlonkowska, Anna, Pogosova, Nana, Weimar, Christian, Iqbal, Romaina, Diaz, Rafael, Yusoff, Khalid, Yusufali, Afzalhussein, Oguz, Aytekin, Wang, Xingyu, Penaherrera, Ernesto, Lanas, Fernando, Ogah, Okechukwu S, Ogunniyi, Adesola, Iversen, Helle K, Malaga, German, Rumboldt, Zvonko, Oveisgharan, Shahram, Al Hussain, Fawaz, Magazi, Daliwonga, Nilanont, Yongchai, Ferguson, John, Pare, Guillaume, and Yusuf, Salim
- Published
- 2016
- Full Text
- View/download PDF
153. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study
- Author
-
O'Donnell, Martin J., Eikelboom, John W., Yusuf, Salim, Diener, Hans-Christoph, Hart, Robert G., Smith, Eric E., Gladstone, David J., Sharma, Mukul, Dias, Rafael, Flaker, Greg, Avezum, Alvaro, Zhu, Jun, Lewis, Gayle, and Connolly, Stuart
- Published
- 2016
- Full Text
- View/download PDF
154. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies
- Author
-
Mente, Andrew, O'Donnell, Martin, Rangarajan, Sumathy, Dagenais, Gilles, Lear, Scott, McQueen, Matthew, Diaz, Rafael, Avezum, Alvaro, Lopez-Jaramillo, Patricio, Lanas, Fernando, Li, Wei, Lu, Yin, Yi, Sun, Rensheng, Lei, Iqbal, Romaina, Mony, Prem, Yusuf, Rita, Yusoff, Khalid, Szuba, Andrzej, Oguz, Aytekin, Rosengren, Annika, Bahonar, Ahmad, Yusufali, Afzalhussein, Schutte, Aletta Elisabeth, Chifamba, Jephat, Mann, Johannes F E, Anand, Sonia S, Teo, Koon, and Yusuf, S
- Published
- 2016
- Full Text
- View/download PDF
155. Prevention and Control of Cardiovascular Diseases: Policies, Strategies, and Interventions
- Author
-
Avezum, Álvaro, Jr., Targueta, Gabriel Pelegrineti, Andrade, Jadelson, editor, Pinto, Fausto, editor, and Arnett, Donna, editor
- Published
- 2015
- Full Text
- View/download PDF
156. A176 ASSOCIATIONS OF ANTIBIOTICS, HORMONAL THERAPIES, ORAL CONTRACEPTIVES, AND LONG-TERM NSAIDS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE PROSPECTIVE URBAN RURAL EPIDEMIOLOGY (PURE) STUDY
- Author
-
C Pray, N Narula, E C Wong, J K Marshall, S Rangarajan, S Islam, A Bahonar, K F Alhabib, A Kontsevaya, F Ariffin, H U Co, W Al Sharief, A Szuba, A Wielgosz, M L Diaz, R Yusuf, L Kruger, B Soman, Y Li, C Wang, L Yin, M Erkin, F Lanas, K Davletov, A Rosengren, P Lopez-Jaramillo, R Khatib, A Oguz, R Iqbal, K Yeates, Á Avezum, W Reinisch, P Moayyedi, and S Yusuf
- Abstract
Background The pathogenesis of inflammatory bowel disease (IBD) which includes Crohn’s disease (CD) and ulcerative colitis (UC), is believed to involve activation of the intestinal immune system in response to the gut microbiome among genetically susceptible hosts. IBD has been historically regarded as a disease of developed nations, though in the past two decades there has been a reported shift in the epidemiological pattern of disease. High-income nations with known high prevalence of disease are seeing a stabilization of incident cases, while a rapid rise of incident IBD is being observed in developing nations. This suggests that environmental exposures may play a role in mediating the risk of developing IBD. The potential environmental determinants of IBD across various regions is vast, though medications have been increasingly recognized as one broad category of risk factors. Purpose Several medications have been considered to contribute to the etiology of IBD. This study assessed the association between medication use and risk of developing IBD using the Prospective Urban Rural Epidemiology (PURE) cohort. Method This was a prospective cohort study of 133,137 individuals between the ages of 20-80 from 24 countries. Country-specific validated questionnaires documented baseline and follow-up medication use. Participants were followed prospectively at least every 3 years. The main outcome was development of IBD, including CD and UC. Short-term (baseline but not follow-up use) and long-term use (baseline and subsequent follow-up use) was evaluated. Results are presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI). Result(s) During the median follow-up of 11.0 years [interquartile range (IQR) 9.2-12.2], we recorded 571 incident cases of IBD (143 CD and 428 UC). Higher risk of incident IBD was associated with baseline antibiotic use [aOR: 2.81 (95% CI: 1.67-4.73), p=0.0001] and hormonal medication use [aOR: 4.43 (95% CI: 1.78-11.01), p=0.001]. Among females, previous or current oral contraceptive use was also associated with IBD development [aOR: 2.17 (95% CI: 1.70-2.77), p=5.02E-10]. NSAID users were also observed to have increased risk of IBD [aOR: 1.80 (95% CI: 1.23-2.64), p=0.002], which was driven by long-term users [aOR: 5.58 (95% CI: 2.26-13.80), p Conclusion(s) Antibiotics, hormonal medications, oral contraceptives, and long-term NSAID use were associated with increased odds of incident IBD after adjustment for covariates. Please acknowledge all funding agencies by checking the applicable boxes below Other Please indicate your source of funding below: Salim Yusuf is supported by the Heart & Stroke Foundation/Marion W. Burke Chair in Cardiovascular Disease. The PURE Study is an investigator-initiated study funded by the Population Health Research Institute, the Canadian Institutes of Health Research (CIHR), Heart and Stroke Foundation of Ontario, support from CIHR’s Strategy for Patient Oriented Research (SPOR) through the Ontario SPOR Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies, with major contributions from AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, and GlaxoSmithkline, and additional contributions from Novartis and King Pharma and from various national or local organisations in participating countries; these include: Argentina: Fundacion ECLA; Bangladesh: Independent University, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de la Frontera; China: National Center for Cardiovascular Diseases; Colombia: Colciencias, grant number 6566-04-18062; India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia, grant numbers 100 -IRDC/BIOTEK 16/6/21 (13/2007) and 07-05-IFN-BPH 010, Ministry of Higher Education of Malaysia grant number 600 -RMI/LRGS/5/3 (2/2011), Universiti Teknologi MARA, Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010); occupied Palestinian territory: the UN Relief and Works Agency for Palestine Refugees in the Near East, occupied Palestinian territory; International Development Research Centre, Canada; Philippines: Philippine Council for Health Research & Development; Poland: Polish Ministry of Science and Higher Education grant number 290/W-PURE/2008/0, Wroclaw Medical University; Saudi Arabia: the Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (research group number RG -1436-013); South Africa: the North-West University, SANPAD (SA and Netherlands Programme for Alternative Development), National Research Foundation, Medical Research Council of SA, The SA Sugar Association (SASA), Faculty of Community and Health Sciences (UWC); Sweden: grants from the Swedish state under the Agreement concerning research and education of doctors; the Swedish Heart and Lung Foundation; the Swedish Research Council; the Swedish Council for Health, Working Life and Welfare, King Gustaf V’s and Queen Victoria Freemasons Foundation, AFA Insurance, Swedish Council for Working Life and Social Research, Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning, grant from the Swedish State under the Läkar Utbildnings Avtalet agreement, and grant from the Västra Götaland Region; Turkey: Metabolic Syndrome Society, AstraZeneca, Turkey, Sanofi Aventis, Turkey; United Arab Emirates (UAE): Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences and Dubai Health Authority, Dubai UAE. Disclosure of Interest C. Pray: None Declared, N. Narula Grant / Research support from: Neeraj Narula holds a McMaster University Department of Medicine Internal Career Award. Neeraj Narula has received honoraria from Janssen, Abbvie, Takeda, Pfizer, Merck, and Ferring, E. C. Wong: None Declared, J. K. Marshall Grant / Research support from: John K. Marshall has received honoraria from Janssen, AbbVie, Allergan, Bristol-Meyer-Squibb, Ferring, Janssen, Lilly, Lupin, Merck, Pfizer, Pharmascience, Roche, Shire, Takeda and Teva., S. Rangarajan: None Declared, S. Islam: None Declared, A. Bahonar: None Declared, K. F. Alhabib: None Declared, A. Kontsevaya: None Declared, F. Ariffin: None Declared, H. U. Co: None Declared, W. Al Sharief: None Declared, A. Szuba: None Declared, A. Wielgosz: None Declared, M. L. Diaz: None Declared, R. Yusuf: None Declared, L. Kruger: None Declared, B. Soman: None Declared, Y. Li: None Declared, C. Wang: None Declared, L. Yin: None Declared, M. Erkin: None Declared, F. Lanas: None Declared, K. Davletov: None Declared, A. Rosengren: None Declared, P. Lopez-Jaramillo: None Declared, R. Khatib: None Declared, A. Oguz: None Declared, R. Iqbal: None Declared, K. Yeates: None Declared, Á. Avezum: None Declared, W. Reinisch Consultant of: Speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult, Consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, Omass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC, Advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC, P. Moayyedi: None Declared, S. Yusuf: None Declared
- Published
- 2023
- Full Text
- View/download PDF
157. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
- Author
-
Lonn, Eva, Bosch, Jackie, Pogue, Janice, Avezum, Alvaro, Chazova, Irina, Dans, Antonio, Diaz, Rafael, Fodor, George J., Held, Claes, Jansky, Petr, Keltai, Matyas, Keltai, Katalin, Kunti, Kamlesh, Kim, Jae-Hyung, Leiter, Lawrence, Lewis, Basil, Liu, Lisheng, Lopez-Jaramillo, Patricio, Pais, Prem, Parkhomenko, Alexandr, Peters, Ron J.G., Piegas, Leopoldo S., Reid, Christopher M., Sliwa, Karen, Toff, William D., Varigos, John, Xavier, Denis, Yusoff, Khalid, Zhu, Jun, Dagenais, Gilles, and Yusuf, Salim
- Published
- 2016
- Full Text
- View/download PDF
158. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial
- Author
-
Jolly, Sanjit S, Cairns, John A, Yusuf, Salim, Rokoss, Michael J, Gao, Peggy, Meeks, Brandi, Kedev, Sasko, Stankovic, Goran, Moreno, Raul, Gershlick, Anthony, Chowdhary, Saqib, Lavi, Shahar, Niemela, Kari, Bernat, Ivo, Cantor, Warren J, Cheema, Asim N, Steg, Philippe Gabriel, Welsh, Robert C, Sheth, Tej, Bertrand, Olivier F, Avezum, Alvaro, Bhindi, Ravinay, Natarajan, Madhu K, Horak, David, Leung, Raymond C M, Kassam, Saleem, Rao, Sunil V, El-Omar, Magdi, Mehta, Shamir R, Velianou, James L, Pancholy, Samir, and Džavík, Vladimír
- Published
- 2016
- Full Text
- View/download PDF
159. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data
- Author
-
Khatib, Rasha, McKee, Martin, Shannon, Harry, Chow, Clara, Rangarajan, Sumathy, Teo, Koon, Wei, Li, Mony, Prem, Mohan, Viswanathan, Gupta, Rajeev, Kumar, Rajesh, Vijayakumar, Krishnapillai, Lear, Scott A, Diaz, Rafael, Avezum, Alvaro, Lopez-Jaramillo, Patricio, Lanas, Fernando, Yusoff, Khalid, Ismail, Noorhassim, Kazmi, Khawar, Rahman, Omar, Rosengren, Annika, Monsef, Nahed, Kelishadi, Roya, Kruger, Annamarie, Puoane, Thandi, Szuba, Andrzej, Chifamba, Jephat, Temizhan, Ahmet, Dagenais, Gilles, Gafni, Amiram, and Yusuf, Salim
- Published
- 2016
- Full Text
- View/download PDF
160. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial
- Author
-
Kelley R.H. Branch, Gilles R. Dagenais, Alvaro Avezum, Jan Basile, Ignacio Conget, William C. Cushman, Petr Jansky, Mark Lakshmanan, Fernando Lanas, Lawrence A. Leiter, Prem Pais, Nana Pogosova, Peter J. Raubenheimer, Lars Ryden, Jonathan E. Shaw, Wayne H.H. Sheu, Theodora Temelkova‐Kurktschiev, M. Angelyn Bethel, Hertzel C. Gerstein, Ramasundarahettige Chinthanie, and Jeffrey L. Probstfield
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2022
- Full Text
- View/download PDF
161. Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation
- Author
-
Stuart J, Connolly, Ganesan, Karthikeyan, Mpiko, Ntsekhe, Abraham, Haileamlak, Ahmed, El Sayed, Alaa, El Ghamrawy, Albertino, Damasceno, Alvaro, Avezum, Antonio M L, Dans, Bernard, Gitura, Dayi, Hu, Emmanuel R, Kamanzi, Fathi, Maklady, Golden, Fana, J Antonio, Gonzalez-Hermosillo, John, Musuku, Khawar, Kazmi, Liesl, Zühlke, Lillian, Gondwe, Changsheng, Ma, Maria, Paniagua, Okechukwu S, Ogah, Onkabetse J, Molefe-Baikai, Peter, Lwabi, Pilly, Chillo, Sanjib K, Sharma, Tantchou T J, Cabral, Wadea M, Tarhuni, Alexander, Benz, Martin, van Eikels, Amy, Krol, Divya, Pattath, Kumar, Balasubramanian, Sumathy, Rangarajan, Chinthanie, Ramasundarahettige, Bongani, Mayosi, Salim, Yusuf, and T, Mpofu
- Subjects
Male ,Vitamin K ,Rheumatic Heart Disease ,Anticoagulants ,Hemorrhage ,General Medicine ,Middle Aged ,Stroke ,Treatment Outcome ,Rivaroxaban ,Echocardiography ,Atrial Fibrillation ,Humans ,Female ,Warfarin ,Factor Xa Inhibitors - Abstract
Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited.We enrolled patients with atrial fibrillation and echocardiographically documented rheumatic heart disease who had any of the following: a CHAOf 4565 enrolled patients, 4531 were included in the final analysis. The mean age of the patients was 50.5 years, and 72.3% were women. Permanent discontinuation of trial medication was more common with rivaroxaban than with vitamin K antagonist therapy at all visits. In the intention-to-treat analysis, 560 patients in the rivaroxaban group and 446 in the vitamin K antagonist group had a primary-outcome event. Survival curves were nonproportional. The restricted mean survival time was 1599 days in the rivaroxaban group and 1675 days in the vitamin K antagonist group (difference, -76 days; 95% confidence interval [CI], -121 to -31; P0.001). A higher incidence of death occurred in the rivaroxaban group than in the vitamin K antagonist group (restricted mean survival time, 1608 days vs. 1680 days; difference, -72 days; 95% CI, -117 to -28). No significant between-group difference in the rate of major bleeding was noted.Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.).
- Published
- 2022
- Full Text
- View/download PDF
162. Agropecuária, meio ambiente e desenvolvimento sustentável
- Author
-
ENDO, Carlos Hisao, primary, FERREIRA JUNIOR, Carlos Joel, additional, PEIXOTO, Érica Rosana Silveira, additional, SILVA, Yuri Laio Teixeira Veras, additional, SILVA, Nathállya Etyenne Figueira, additional, OLIVEIRA, Danilo Moraes de, additional, LIMA-FILHO, Dario de Oliveira, additional, GOULART, Gislayne da Silva, additional, MACIEL, Adrianne Pureza, additional, SILVA, Bruna Roldão da, additional, RIBEIRO, Rita Suselaine Vieira, additional, CANEVER, Lara, additional, HOFFMANN, Fernando Leite, additional, GUIMARÃES, Paula Rosane Vieira, additional, GONÇALVES, Marcos Falcão, additional, ALEXOPOULOS, Joanna Georgios, additional, SILVA, Gleiciane Teodoro da, additional, VITAL, Tales, additional, ANDRADE, Cézar Augusto Lins de, additional, BONIFÁCIO, Renata Danielle Torres, additional, COSTA, Lucas Renato Espuri, additional, DORNELAS, Myriam Angélica, additional, BARBOSA, Rosemary Pereira Costa e, additional, PRADO, José Willer do, additional, VIEIRA, Kelly Carvalho, additional, PEREIRA, Mirian Rosa, additional, SIQUEIRA, Karolline Fernandes, additional, SOUZA, Eliane Moreira de Sá, additional, SPANEVELLO, Rosani Marisa, additional, BOSCARDIN, Mariele, additional, LAGO, Adriano, additional, TOLEDO, Vitória Benedetti de, additional, LUDKE, Queila, additional, LANDMANN, Oscar Frederico Accioly Venturato, additional, FERRANTE, Vera Lucia Silveira Botta, additional, CASTRO, Marcus César Avezum Alves de, additional, RIBEIRO, Maria Lúcia, additional, ROCHA, Danillo C, additional, SOUZA, Eliane Moreira Sá de, additional, CAETANO, Mauro, additional, ANANIAS, Dayanne Darth, additional, LOPES, Amanda, additional, SILVA, Cláudio Eurico S F da, additional, COSTA, José Eloízio da, additional, CARVALHO, Diana Mendonça de, additional, ALCÂNTARA, Fernanda Viana de, additional, SOUSA, James José Brito, additional, BORGES, Beatriz dos Santos, additional, BARROS, Cynthia da Silva, additional, SILVA, Selmo Antonio da, additional, SANTOS, Márcio Rezende, additional, DANTAS, André Augusto Nobrega, additional, MARCHIORI, Antônio Carlos Caetano, additional, VEJA, Silvia Moreira Rojo, additional, VIEGAS, Isabel Fernandes Pinto, additional, TURCO, Patrícia Helena Nogueira, additional, OTANI, Malimiria Norico, additional, AZEVEDO, Cleide, additional, MACHADO, Cristino, additional, SIQUEIRA, Paulo Henrique de Lima, additional, BRUM, Tonia Magali Moraes, additional, MORAES, Jorge André Ribas, additional, SILVA, André Luiz Emmel, additional, KAUFMANN, Antônio Alex, additional, MADRID, Rosemeri da Silva, additional, CERQUEIRA-ADÃO, Sebastião Ailton da Rosa, additional, BAYMA, Márcio Muniz Albano, additional, SÁ, Claudenor Pinho de, additional, PAPA, Daniel de Almeida, additional, CAETANO, Francisco Aquiles de Oliveira, additional, FEITOSA, Milena Monteiro, additional, SILVA, Edson Arlindo, additional, SANTOS, Luana Ferreira dos, additional, DIAS, Marcelo Miná, additional, SALGADO, Rafael Júnior dos Santos Figueiredo, additional, CUNHA, Wellington Alvim da, additional, FIGUEIRA, Sérgio Rangel Fernandes, additional, BELIK, Walter, additional, VICENTE, Andrea koga, additional, CARVALHO, Abner Vilhena de, additional, CARVALHO, Rhayza Alves Figueiredo de, additional, GUIMARÃES, Jarsen Luis Castro, additional, SANTOS, Zilda Joaquina Cohen Gama dos, additional, CARVALHO, Ednéa do Nascimento, additional, ALMEIDA, Rodolfo Maduro, additional, ATAIDE, João Antônio da Rocha, additional, SANTOS, Julio Marcel, additional, PEIXOTO, Francisco José, additional, ZANCAN, Rosário Claudio, additional, SOUZA, Waldemar Antonio da Rcoha de, additional, CONDÉ, Giuliano Magno de Oliveira, additional, NOGUEIRA, Heloisa Guimarães Peixoto, additional, MARQUES, Ieso Costa, additional, MACHADO JÚNIOR, Eliseu Vieira, additional, NUNES, Aline Corrêa, additional, BECKER, Cláudio, additional, OLIVEIRA, Nilton Marques de, additional, ROCHA JR, Weimar Freire da, additional, MARTINS, Matteus Guimarães, additional, ANDRADE, Manoel Pereira, additional, IADANZA, Enaile, additional, NUNES, Emanoel Márcio, additional, CRUZ, Mônica Soares, additional, MATOS FILHO, João, additional, CAVALCANTI, Daniella Medeiros, additional, LIMA, Aparecida de Fátima Alves de, additional, DUMER, Miguel Carlos Ramos, additional, MARQUES, Beatriz Rodrigues, additional, ANDRADE, Ana Carolina Júlio da Silva, additional, NUNES, Pauliny de Souza, additional, MACIEL, Wilson Ravelli Elizeu, additional, WEIMER, Marciano Rodrigo, additional, SILVA, Ivanir Salete Tecchio da, additional, RAMOS, Fernando Maciel, additional, ZUCCHI, Cristiane, additional, GARCIA, Vitor Pires, additional, WOHLENBERG, Janaína, additional, ALBANO, Claudio Sonaglio, additional, BOLTER, Jairo Alfredo Genz, additional, HAAS, Jaqueline Mallmann, additional, GADOMSKI, Sirlei Terezinha, additional, BORTOLOTTI, Mônica Aparecida, additional, FRANÇA, Mauricila de Campos, additional, TAVARES, Luzyanna Rocha, additional, TRAVASSOS, Guilherme Fonseca, additional, PINHA, Lucas Campio, additional, CARNEIRO, Alziro Vasconcelos, additional, ALBINO, Pablo Murta Baião, additional, MEDEIROS, Vitor Antenor Sales, additional, GRZEBIELUCKAS, Cleci, additional, SANTOS, Josiane Silva Costa dos, additional, RIBEIRO, Magno Alves, additional, SGUAREZI, Sandro Benedito, additional, GOMES, Adriano Provezano, additional, DIAS, Matheus Alves, additional, NASCIF, Christiano, additional, ERVILHA, Gabriel Teixeira, additional, FINAMORE, Eduardo Belisário, additional, LEAL, Liliane Vieira Martins, additional, PRADO, Cássio Augusto, additional, BATTISTI, Luciano de Oliveira, additional, PASQUALOTTO, Nayara, additional, HARTMANN, Renata de Baco, additional, BOHNER, Tanny Oliveira Lima, additional, WIZNIEWSKY, José Geraldo, additional, BARCELOS, Catarina Oliveira Guimarães, additional, REIS, Carlos Vinícius Santos, additional, SILVA, Swasilanne da Fonseca e, additional, COSTA, Gilson, additional, MACIEL, Hilaíres, additional, MARQUES, Allan Rodrigues dos Santos, additional, LOURENZANI, Ana Elisa Bressan Smith, additional, VIEIRA, Adriana Carvalho Pinto, additional, FERRARINI, Angel dos Santos Fachinelli, additional, MORAES, Márcia Azanha Ferraz Dias de, additional, BEZERRA, Cédma Adriádina Gondim, additional, MAIA, Ana Cristina Nogueira, additional, COSTA, Genivalda Cordeiro da, additional, SILVA, Etevaldo Almeida, additional, MACHADO, Sandilla de Oliveira, additional, ALECRIM, Geandro Machado, additional, LIMA, Gerinaldo da Silva, additional, SANTOS, Edith lemos Ornellas dos, additional, SCHIMANKO, Alexandra Ribeiro de Souza, additional, ABICHT, Alexandre de Melo, additional, CEOLIN, Alessandra Carla, additional, OLIVEIRA, Thayronne Santos, additional, FREITAS, Jessica Viana de, additional, SILVA, Paulo César Lima, additional, NASCIMENTO, Rudgero Oliveira do, additional, FERREIRA, Felipe Ungarato, additional, PINHEIRO, Nathália Marcia Goulart, additional, ORDONEZ, Robert Eduardo Cooper, additional, ESCAMIA, João Henrique, additional, DEDINI, Franco Giuseppe, additional, MOREIRA, Adriana Rochas de Carvalho Fruguli, additional, OLIVEIRA, Aparecida Antonia, additional, LIMA, Eleuza Ferreira, additional, MORETTI, Silvana Aparecida Lucato, additional, DUARTE, Meire Eugênia, additional, GOMES, Joaquim Octaviano Pinto, additional, ALBUQUERQUE NETO, Leovigildo Cavalcanti de, additional, CHIOVETO, Arnaldo Taveira, additional, PIFFER, Moacir, additional, ORLANDI, Marines, additional, OHIRA, Luis Antonio Shigueharu, additional, SOUSA, Lucas Vitor de Carvalho, additional, NOGUEIRA, Jorge Madeira, additional, SANTOS, Beatriz Leite dos, additional, and ROSAS, Verônica Heloisa, additional
- Published
- 2019
- Full Text
- View/download PDF
163. Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis
- Author
-
Eikelboom, John W., Connolly, Stuart J., Bosch, Jacqueline, Shestakovska, Olga, Aboyans, Victor, Alings, Marco, Anand, Sonia S., Avezum, Alvaro, Berkowitz, Scott D., Bhatt, Deepak L., Cook-Bruns, Nancy, Felix, Camilo, Fox, Keith A.A., Hart, Robert G., Maggioni, Aldo P., Moayyedi, Paul, O’Donnell, Martin, Rydén, Lars, Verhamme, Peter, Widimsky, Petr, Zhu, Jun, and Yusuf, Salim
- Published
- 2019
- Full Text
- View/download PDF
164. Prevalence, awareness, treatment and control of hypertension in rural and urban communities in Latin American countries
- Author
-
Lamelas, Pablo, Diaz, Rafael, Orlandini, Andres, Avezum, Alvaro, Oliveira, Gustavo, Mattos, Antonio, Lanas, Fernando, Seron, Pamela, Oliveros, Maria J., Lopez-Jaramillo, Patricio, Otero, Johanna, Camacho, Paul, Miranda, Jaime, Bernabe-Ortiz, Antonio, Malaga, German, Irazola, Vilma, Gutierrez, Laura, Rubinstein, Adolfo, Castellana, Noelia, Rangarajan, Sumathy, and Yusuf, Salim
- Published
- 2019
- Full Text
- View/download PDF
165. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial
- Author
-
Branch, Kelley R., Probstfield, Jeffrey L., Eikelboom, John W., Bosch, Jackie, Maggioni, Aldo P., Cheng, Richard K., Bhatt, Deepak L., Avezum, Alvaro, Fox, Keith A.A., Connolly, Stuart J., Shestakovska, Olga, and Yusuf, Salim
- Published
- 2019
- Full Text
- View/download PDF
166. SUBSÍDIOS PARA ELABORAÇÃO DE PLANO MUNICIPAL PARA GESTÃO DA FRAÇÃO ORGÂNICA DE RESÍDUOS SÓLIDOS DOMICILIARES PARA O MUNICÍPIO DE RIO CLARO-SP
- Author
-
Elisa Fonseca Horta and Marcus César Avezum Alves Castro
- Subjects
gestão de resíduos sólidos, plano municipal de resíduos sólidos, resíduos orgânicos. ,Education (General) ,L7-991 ,Special aspects of education ,LC8-6691 - Abstract
A pesquisa propôs subsídios para elaboração de plano municipal para a gestão dos resíduos orgânicos. O universo da pesquisa foram os estabelecimentos da tipologia hortifrútis, compostos por mercados e verdurões. A partir da seleção da amostra foram obtidos os seguintes dados em campo: quantidade gerada, destino dos resíduos, segregação dos resíduos e frequência de coleta. A partir destes dados, estimou-se a geração total de resíduos orgânicos deste segmento no município, os custos para implantação e operação de uma central de compostagem, e as formas de cobrança dos geradores para a sustentabilidade financeira do sistema. De acordo com os resultados, cada estabelecimento gera, em média, 105 t/mês de resíduos, sendo 35 t/mês de orgânicos. Dos estabelecimentos entrevistados, 94% fazem a segregação na fonte dos resíduos, sinalizando que a proposta de gestão dos resíduos orgânicos pode ser aplicada sem muitas alterações na rotina já existente nos estabelecimentos. O custo de implantação da central de compostagem foi estimado em R$165 mil e o de operação em R$10 mil/mês. Foram desenvolvidos dois modelos de cobrança, um que tem como base o número de caixas registradoras (check-outs) e outro baseado no número de recipientes (cestas) coletados de resíduo por estabelecimento, ambos consideram o porte do estabelecimento. Os resultados sinalizam que o número de check-outs existentes nos estabelecimentos pode ser utilizado para formular os valores do sistema de cobrança. Assim, o custo mensal para ambos modelos está entre as faixas: Pequeno de R$75,44/mês a R$334,88/mês; Pequeno/Médio de R$295,04/mês a R$898,88/mês; e Médio de R$357,44/mês a R$1462,88/mês.
- Published
- 2017
- Full Text
- View/download PDF
167. Understanding and optimization of rapid and small-scale germination process on the nutritional quality of lentil and cowpea
- Author
-
Méot, Jean-Michel, Delpech, Charlotte, Avezum, Luiza, Rajjou, Loïc, Mestres, Christian, Achir, Nawel, Madode, Yann Emeric, Gibert, Olivier, Verdeil, Jean-Luc, Rondet, Eric, Méot, Jean-Michel, Delpech, Charlotte, Avezum, Luiza, Rajjou, Loïc, Mestres, Christian, Achir, Nawel, Madode, Yann Emeric, Gibert, Olivier, Verdeil, Jean-Luc, and Rondet, Eric
- Published
- 2023
168. Impact of pH and temperature on a-galactosides diffusion and degradation during steeping and cooking processes of chickpea, lentils, and beans
- Author
-
Siguemoto, Erica, Mestres, Christian, Ollier, Léa, Avezum, Luiza, Siguemoto, Erica, Mestres, Christian, Ollier, Léa, and Avezum, Luiza
- Published
- 2023
169. Sleep Patterns and the Risk of Acute Stroke
- Author
-
Mc Carthy, Christine Eileen, primary, Yusuf, Salim, additional, Judge, Conor, additional, Alvarez-Iglesias, Alberto, additional, Hankey, Graeme J., additional, Oveisgharan, Shahram, additional, Damasceno, Albertino, additional, Iversen, Helle Klingenberg, additional, Rosengren, Annika, additional, Avezum, Alvaro, additional, Lopez-Jaramillo, Patricio, additional, Xavier, Denis, additional, Wang, Xingyu, additional, Rangarajan, Sumathy, additional, and O'Donnell, Martin, additional
- Published
- 2023
- Full Text
- View/download PDF
170. AVALIAÇÃO DA PERCEPÇÃO DA EQUIPE DE ENFERMAGEM SOBRE A PRÁTICA DE HIGIENIZAÇÃO ORAL EM UNIDADE DE TERAPIA INTENSIVA
- Author
-
Reis, Heloísa de Milano Friedmann, primary, Avezum, Gabriella, additional, Medeiros, Ana Carolina de Andrade Buhatem, additional, De Araújo, Mara Nogueira, additional, and Cantoni, Valéria Cristina de Souza, additional
- Published
- 2023
- Full Text
- View/download PDF
171. Improving GPS-Based Mode of Transport Detection in Multi-Modal Trips using Stop Analysis
- Author
-
Klinker, Jens, primary, Avezum-Mercer, Mariana, additional, and Jonas, Stephan, additional
- Published
- 2023
- Full Text
- View/download PDF
172. Presenting a Statistical Approach for Transforming Standardized German Traffic Surveys into Origin-Destination Matrices
- Author
-
Klinker, Jens, primary, Yu, Joe, additional, Avezum-Mercer, Mariana, additional, and Jonas, Stephan, additional
- Published
- 2023
- Full Text
- View/download PDF
173. Population health impact and economic evaluation of the CARDIO4Cities approach to improve urban hypertension management
- Author
-
Reiker, Theresa, primary, Des Rosiers, Sarah, additional, Boch, Johannes, additional, Partha, Gautam, additional, Venkitachalam, Lakshmi, additional, Santana, Adela, additional, Srivasatava, Abhinav, additional, Barboza, Joseph, additional, Byambasuren, Enkhtuya, additional, Baxter, Yara C., additional, Dib, Karina Mauro, additional, Dashdorj, Naranjargal, additional, Anne, Malick, additional, de Oliveira, Renato W., additional, Silveira, Mariana, additional, Ferrer, Jose M. E., additional, Morgan, Louise, additional, Jones, Olivia, additional, Luvsansambuu, Tumurbaatar, additional, Bortolotto, Luiz Aparecido, additional, Drager, Luciano, additional, Avezum, Alvaro, additional, and Aerts, Ann, additional
- Published
- 2023
- Full Text
- View/download PDF
174. Stroke in Latin America: Burden of Disease and Opportunities for Prevention
- Author
-
Avezum, Álvaro, Costa-Filho, Francisco F., Pieri, Alexandre, Martins, Sheila O., and Marin-Neto, José A.
- Published
- 2015
- Full Text
- View/download PDF
175. Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study
- Author
-
Smyth, Andrew, Teo, Koon K, Rangarajan, Sumathy, O'Donnell, Martin, Zhang, Xiaohe, Rana, Punam, Leong, Darryl P, Dagenais, Gilles, Seron, Pamela, Rosengren, Annika, Schutte, Aletta E, Lopez-Jaramillo, Patricio, Oguz, Ayetkin, Chifamba, Jephat, Diaz, Rafael, Lear, Scott, Avezum, Alvaro, Kumar, Rajesh, Mohan, Viswanathan, Szuba, Andrzej, Wei, Li, Yang, Wang, Jian, Bo, McKee, Martin, and Yusuf, Salim
- Published
- 2015
- Full Text
- View/download PDF
176. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial
- Author
-
Whitlock, Richard P, Devereaux, P J, Teoh, Kevin H, Lamy, Andre, Vincent, Jessica, Pogue, Janice, Paparella, Domenico, Sessler, Daniel I, Karthikeyan, Ganesan, Villar, Juan Carlos, Zuo, Yunxia, Avezum, Álvaro, Quantz, Mackenzie, Tagarakis, Georgios I, Shah, Pallav J, Abbasi, Seyed Hesameddin, Zheng, Hong, Pettit, Shirley, Chrolavicius, Susan, and Yusuf, Salim
- Published
- 2015
- Full Text
- View/download PDF
177. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study
- Author
-
Leong, Darryl P, Teo, Koon K, Rangarajan, Sumathy, Lopez-Jaramillo, Patricio, Avezum, Alvaro, Jr, Orlandini, Andres, Seron, Pamela, Ahmed, Suad H, Rosengren, Annika, Kelishadi, Roya, Rahman, Omar, Swaminathan, Sumathi, Iqbal, Romaina, Gupta, Rajeev, Lear, Scott A, Oguz, Aytekin, Yusoff, Khalid, Zatonska, Katarzyna, Chifamba, Jephat, Igumbor, Ehimario, Mohan, Viswanathan, Anjana, Ranjit Mohan, Gu, Hongqiu, Li, Wei, and Yusuf, Salim
- Published
- 2015
- Full Text
- View/download PDF
178. Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up
- Author
-
Alnasser, Sami M.A., Huang, Wei, Gore, Joel M., Steg, Ph. Gabriel, Eagle, Kim A., Anderson, Frederick A., Jr., Fox, Keith A.A., Gurfinkel, Enrique, Brieger, David, Klein, Werner, van de Werf, Frans, Avezum, Álvaro, Montalescot, Gilles, Gulba, Dietrich C., Budaj, Andrzej, Lopez-Sendon, Jose, Granger, Christopher B., Kennelly, Brian M., Goldberg, Robert J., Fleming, Emily, and Goodman, Shaun G.
- Published
- 2015
- Full Text
- View/download PDF
179. Prevalência de tromboembolismo pulmonar por imagem tomográfica nos pacientes COVID-19, em uma cidade do noroeste paulista / Prevalence of pulmonary thromboembolism by tomographic imaging in COVID-19 patients in a city in northwestern São Paulo
- Author
-
Raíssa Marjory Zonta Moreti, Marina Coimbra Da Cruz, Carolina Pimentel Bertasso, Luiz Fernando Avezum Do Prado, Ana Carolina Pimenta Grecco Sano, Eduardo Ota Sano, Lucas Coimbra Da Cruz, and Thiago Moreira Da Cruz
- Subjects
Marketing ,Pharmacology ,Organizational Behavior and Human Resource Management ,Strategy and Management ,Drug Discovery ,Pharmaceutical Science - Abstract
Objetivo: Analisar a ocorrência de tromboembolismo pulmonar da COVID-19 na avaliação por Tomografia de Tórax, comparando as variáveis sexo e idade. Materiais e Métodos: Estudo transversal, retrospectivo, realizado em Fernandópolis-SP, entre abril de 2020 a junho de 2021, com 645 pessoas, acima de 18 anos, positivos para SARS-COV-2, em diferentes estágios da doença, ambulatorial e hospitalar, desconsiderando as comorbidades e tratamentos durante ou após infecção. Realizado a análise da angiotomografia de tórax e quantificação do acometimento pulmonar. Resultados: Houve significância entre a ocorrência de TEP (p=0,001) e o percentual do acometimento pulmonar de 51 a 75% (33,33%), assim como entre o sexo e a faixa etária em relação ao percentual de acometimento pulmonar (p
- Published
- 2022
- Full Text
- View/download PDF
180. Medications for blood pressure, blood glucose, lipids, and anti-thrombotic medications: relationship with cardiovascular disease and death in adults from 21 high-, middle-, and low-income countries with an elevated body mass index
- Author
-
Darryl P Leong, Sumathy Rangarajan, Annika Rosengren, Aytekin Oguz, Khalid F Alhabib, Paul Poirier, Rafael Diaz, Antonio L Dans, Romaina Iqbal, Afzalhussein M Yusufali, Karen Yeates, Jephat Chifamba, Pamela Seron, Jose Lopez-Lopez, Ahmad Bahonar, Li Wei, Hu Bo, Liu Weida, Alvaro Avezum, Rajeev Gupta, Viswanathan Mohan, Herculina S Kruger, P V M Lakshmi, Rita Yusuf, and Salim Yusuf
- Subjects
Epidemiology ,Cardiology and Cardiovascular Medicine - Abstract
Aims Elevated body mass index (BMI) is an important cause of cardiovascular disease (CVD). The population-level impact of pharmacologic strategies to mitigate the risk of CVD conferred by the metabolic consequences of an elevated BMI is not well described. Methods and results We conducted an analysis of 145 986 participants (mean age 50 years, 58% women) from 21 high-, middle-, and low-income countries in the Prospective Urban and Rural Epidemiology study who had no history of cancer, ischaemic heart disease, heart failure, or stroke. We evaluated whether the hazards of CVD (myocardial infarction, stroke, heart failure, or cardiovascular death) differed among those taking a cardiovascular medication (n = 29 174; including blood pressure-lowering, blood glucose-lowering, cholesterol-lowering, or anti-thrombotic medications) vs. those not taking a cardiovascular medication (n = 116 812) during 10.2 years of follow-up. Cox proportional hazard models with the community as a shared frailty were constructed by adjusting age, sex, education, geographic region, physical activity, tobacco, and alcohol use. We observed 7928 (5.4%) CVD events and 9863 (6.8%) deaths. Cardiovascular medication use was associated with different hazards of CVD (interaction P < 0.0001) and death (interaction P = 0.0020) as compared with no cardiovascular medication use. Among those not taking a cardiovascular medication, as compared with those with BMI 20 to Conclusion To the extent that CVD risk among those with an elevated BMI is related to hypertension, diabetes, and an elevated thrombotic milieu, targeting these pathways pharmacologically may represent an important complementary means of reducing the CVD burden caused by an elevated BMI.
- Published
- 2022
- Full Text
- View/download PDF
181. Improving the nutritional quality of pulses via germination
- Author
-
Luiza Avezum, Eric Rondet, Christian Mestres, Nawel Achir, Yann Madode, Olivier Gibert, Charlotte Lefevre, Youna Hemery, Jean-Luc Verdeil, Loïc Rajjou, Démarche intégrée pour l'obtention d'aliments de qualité (UMR QualiSud), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut de Recherche pour le Développement (IRD)-Avignon Université (AU)-Université de La Réunion (UR)-Institut Agro Montpellier, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Université de Montpellier (UM), Université Paris-Saclay, Université d’Abomey-Calavi - Faculté des sciences agronomiques (UAC FSA), Université d’Abomey-Calavi = University of Abomey Calavi (UAC), Amélioration génétique et adaptation des plantes méditerranéennes et tropicales (UMR AGAP), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro Montpellier, Département Systèmes Biologiques (Cirad-BIOS), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad), Département Performances des systèmes de production et de transformation tropicaux (Cirad-PERSYST), Institut Jean-Pierre Bourgin (IJPB), AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Labex [AGRO 2011-LABX-002]
- Subjects
F60 - Physiologie et biochimie végétale ,General Chemical Engineering ,Composition des aliments ,seeds ,Q02 - Traitement et conservation des produits alimentaires ,Traitement des aliments ,[SDV.IDA]Life Sciences [q-bio]/Food engineering ,Légumineuse à grains ,Q04 - Composition des produits alimentaires ,Semence ,Pulses ,nutritional compounds ,food ,food and beverages ,Amélioration de qualités nutritives ,Valeur nutritive ,germination ,Plantule ,processing ,[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition ,Food Science - Abstract
International audience; Germination is a traditional process and a re-emerging trend in healthy foods, resulting a progressively increase in scientific research on their nutritional traits and phytochemical contents. This review examines the physiological and biochemical changes during the germination sensu stricto in pulses, taking into consideration the genotype, environmental conditions, hormone control, and the metabolic transition from seed to seedling. Germination sensu stricto is achieved as soon as elongation of the radicle, implies heterotrophy metabolism; further thermal processing is needed before consumption. In contrast, seedlings production requires a long period of imbibition and can provide a ready-to-eat food product. Furthermore, proteins, carbohydrates, minerals, vitamins, and antinutritional compounds of pulses are described. Impacts of food processing, such as soaking, germination, and cooking, in nutritional and antinutritional values are also evaluated. The association of soaking, germination, and cooking increases the nutritional values of pulses by increasing protein/starch digestibility and vitamins content and by decreasing antinutritional compounds. The final plant-based product allows versatility in formulation to produce novel food products and/or ingredients with better nutritional content. This can encourage the scientific community, industry, and government to invest in research and development to increase germinated pulse-based food, to replace other products, or to develop new ones.
- Published
- 2022
- Full Text
- View/download PDF
182. Depressive Symptoms and Risk of Acute Stroke: INTERSTROKE Case-Control Study
- Author
-
Murphy, Robert P., Reddin, Catriona, Rosengren, Annika, Judge, Conor, Hankey, Graeme J., Ferguson, John, Alvarez-Iglesias, Alberto, Oveisgharan, Shahram, Wasay, Mohammad, McDermott, Clodagh, Iversen, Helle Klingenberg, Lanas, Fernando, Al-Hussain, Fawaz, Czlonkowska, Anna, Oguz, Aytekin, Ogunniyi, Adesola, Damasceno, Albertino, Xavier, Denis, Avezum, Alvaro, Wang, Xingyu, Langhorne, Peter, Yusuf, Salim, and O'Donnell, Martin
- Subjects
Neurology (clinical) ,Research Article - Abstract
BACKGROUND AND OBJECTIVES: Depression has been reported to be a risk factor of acute stroke, based largely on studies in high-income countries. In the INTERSTROKE study, we explored the contribution of depressive symptoms to acute stroke risk and 1-month outcome across regions of the world, within subpopulations and by stroke type. METHODS: The INTERSTROKE is an international case-control study of risk factors of first acute stroke, conducted in 32 countries. Cases were patients with CT- or MRI-confirmed incident acute hospitalized stroke, and controls were matched for age, sex, and within sites. Standardized questions asked about self-reported depressive symptoms during the previous 12 months and the use of prescribed antidepressant medications were recorded. Multivariable conditional logistic regression was used to determine the association of prestroke depressive symptoms with acute stroke risk. Adjusted ordinal logistic regression was used to explore the association of prestroke depressive symptoms with poststroke functional outcome, measured with the modified Rankin scale at 1 month after stroke. RESULTS: Of 26,877 participants, 40.4% were women, and the mean age was 61.7 ± 13.4 years. The prevalence of depressive symptoms within the last 12 months was higher in cases compared with that in controls (18.3% vs 14.1%, p < 0.001) and differed by region (p interaction
- Published
- 2023
183. Hidroxicloroquina para Pacientes com COVID-19 não Hospitalizados: Uma Revisão Sistemática e Metanálise de Ensaios Clínicos Randomizados
- Author
-
Lucchetta, Rosa, Matuoka, Jessica Y., Oliveira Junior, Haliton Alves de, Oliveira, Gustavo, Cavalcanti, Alexandre Biasi, Azevedo, Luciano, Berwanger, Otavio, Lopes, Renato Delascio, Rosa, Regis Goulart, Veiga, Viviane Cordeiro, and Avezum, Álvaro
- Subjects
Hidroxicloroquina ,Metanálise ,SARS-CoV-2 ,Ensaios Clínicos Controlados Aleatórios como Assunto ,Meta-Analyis ,COVID-19/tratamento farmacológico ,COVID-19/drug therapy ,Hydroxychloroquine ,Randomized Controlled Trials as Topic - Abstract
Resumo Fundamento: Revisões sistemáticas anteriores não identificaram benefício do uso da hidroxicloroquina ou da cloroquina em pacientes com COVID-19 não hospitalizados. Após a publicação dessas revisões, os resultados do COPE, o maior ensaio clínico randomizado até hoje, tornaram-se disponíveis. Objetivos: Conduzir uma revisão sistemática e metanálise de ensaios clínicos randomizados (ECRs) para sintetizar as evidências sobre a eficácia e a segurança da hidroxicloroquina e da cloroquina em pacientes com COVID-19 não hospitalizados em comparação a controle ou tratamento padrão. Métodos: As buscas foram conduzidas nos bancos de dados PubMed, Embase, The Cochrane Library e ClinicalTrials.gov, e complementadas por busca manual. Foram realizadas metanálises diretas e avaliações de risco de viés e certeza da evidência, incluindo análise do tamanho ótimo da informação (OIS, optimal information size). Um nível de significância de 0,05 foi adotado na metanálise. PROSPERO: CRD42021265427. Resultados: Oito ECRs com 3219 participantes foram incluídos. As taxas de internação por COVID-19 e de eventos adversos não foram significativamente diferentes entre hidroxicloroquina (5,6% e 5,1%) e controle (7,4% e 20,4%) [risco relativo (RR) 0,77, intervalo de confiança 95% (IC95%), 0,57-1,04, I2: 0%; RR 1,78, IC95% 0,90; 3,52, I2: 93%, respectivamente)]. O OIS (7880) não foi alcançado para hospitalização por COVID-19, independentemente da simulação para a taxa de evento e redução do RR estimados. Conclusão: A evidência de muito baixa qualidade indicou falta de benefício com hidroxicloroquina em prevenir internações por COVID-19. Apesar de ser a revisão sistemática com o maior número de participantes incluídos, o OIS, considerando a resposta à infecção anterior à vacinação, não foi atingido. Abstract Background: Previous systematic reviews have identified no benefit of hydroxychloroquine and chloroquine in non-hospitalized COVID-19 patients. After publication of these reviews, the results of COPE, the largest randomized trial conducted to date, became available. Objectives: To conduct a systematic review and meta-analyses of randomized clinical trials (RCTs) to synthesize the evidence on the efficacy and safety of hydroxychloroquine and chloroquine for non-hospitalized COVID-19 patients compared to placebo or standard of care. Methods: Searches were conducted in PubMed, Embase, The Cochrane Library, and ClinicalTrials.gov complemented by manual search. Pairwise meta-analyses, risk of bias, and evidence certainty assessments were conducted, including optimal information size analysis (OIS). A level of significance of 0.05 was adopted in the meta-analysis. PROSPERO: CRD42021265427. Results: Eight RCTs with 3,219 participants were included. COVID-19 hospitalization and any adverse events rates were not significantly different between hydroxychloroquine (5.6% and 35.1%) and control (7.4% and 20.4%) (risk ratio, RR, 0.77, 95% confidence interval, CI, 0.57-1.04, I2: 0%; RR 1.78, 95%-CI 0.90; 3.52, I2: 93%, respectively). The OIS (7,880) was not reached for COVID-19 hospitalization, independently of the simulation for anticipated event rate and RR reduction estimate. Conclusion: Evidence of very low certainty showed lack of benefit with hydroxychloroquine in preventing COVID-19 hospitalizations. Despite being the systematic review with the largest number of participants included, the OIS, considering pre-vaccination response to infection, has not yet been reached.
- Published
- 2023
184. Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: Fundamentação e Desenho do Estudo CARE (CARE – Coalition COVID-19 Brazil VIII)
- Author
-
Oliveira, Gustavo B. F., Neves, Precil Diego M. M., Oliveira, Haliton A., Catarino, Daniela Ghidetti Mangas, Alves, Lucas B. O., Cavalcanti, Alexandre B., Rosa, Regis G., Veiga, Viviane C., Azevedo, Luciano C.P., Berwanger, Otávio, Lopes, Renato D., and Avezum, Álvaro
- Subjects
Rivaroxabana ,Treatment Outcome ,Outpatient Clinics, Hospital ,Rivaroxaban ,Trombose ,COVID-19 ,Thrombosis ,Ambulatório Hospitalar ,Resultado do Tratamento - Abstract
Resumo Fundamento Estudos anteriores revelaram alto risco de eventos tromboembólicos arteriais e venosos como consequência de danos virais diretos do SARS-CoV-2 em células endoteliais e um meio procoagulante devido ao aumento de biomarcadores como o D-dímero, fibrinogênio, fator VIII. Foram realizados ensaios controlados randomizados de terapias antitrombóticas em pacientes internados, no entanto, poucos estudos avaliaram o papel da tromboprofilaxia no ambiente ambulatorial. Objetivo Avaliar se a profilaxia antitrombótica com rivaroxabana reduz o risco de eventos trombóticos venosos ou arteriais, suporte ventilatório invasivo e morte em pacientes ambulatoriais com COVID-19. Métodos O estudo CARE é um ensaio randomizado, aberto, multicêntrico e controlado por rivaroxabana 10 mg uma vez por dia durante 14 dias ou tratamento local padrão isolado, para a prevenção de resultados adversos, registrado no Clinicaltrials.gov (NCT04757857). Os critérios de inclusão são adultos com infecção confirmada ou suspeita do SARS-CoV-2, com sintomas leves ou moderados, sem indicação de hospitalização, no prazo de 7 dias após o início dos sintomas e um fator de risco de complicação da COVID-19 (>65 anos, hipertensão, diabetes, asma, doença pulmonar obstrutiva crônica ou outras doenças pulmonares crônicas, tabagismo, imunossupressão ou obesidade). O desfecho primário composto inclui tromboembolismo venoso, necessidade de ventilação mecânica invasiva, eventos cardiovasculares agudos maiores e mortalidade no prazo de 30 dias após a randomização, sendo avaliado segundo o princípio da intenção de tratar. Todos os pacientes assinaram termo de consentimento. Foi estabelecido um nível de significância de 5% para todos os testes estatísticos. Resultados Os principais desfechos trombóticos e hemorrágicos, hospitalizações e mortes serão avaliados centralmente por um comitê de eventos clínicos independente, sob a condição cega para a alocação dos grupos de tratamento. Conclusão O estudo CARE fornecerá informação relevante e contemporânea sobre o possível papel da tromboprofilaxia em pacientes ambulatoriais com COVID-19. Abstract Background Previous studies have demonstrated a high risk of arterial and venous thromboembolic events as a consequence of direct viral damage to endothelial cells by SARS-CoV-2 and a procoagulant milieu due to increased biomarkers, such as D-dimer, fibrinogen, and factor VIII. Although randomized controlled trials of antithrombotic therapies have been conducted in hospitalized patients, few have evaluated the role of thromboprophylaxis in an outpatient setting. Objective To assess whether antithrombotic prophylaxis with rivaroxaban reduces the risk of venous or arterial thrombotic events, invasive ventilatory support, and death in COVID-19 outpatients. Methods The COVID Antithrombotic Rivaroxaban Evaluation (CARE) study, a multicenter, randomized, open-label, controlled trial of rivaroxaban 10 mg once daily for 14 days or local standard treatment alone to prevent adverse outcomes, is registered in clinicaltrials.gov (NCT04757857). The inclusion criteria are adults with confirmed or suspected SARS-CoV-2 infection and mild or moderate symptoms without indication for hospitalization, within 7 days of symptom onset, and 1 risk factor for COVID-19 complication (> 65 years, hypertension, diabetes mellitus, asthma, chronic obstructive pulmonary disease or other chronic lung diseases, smoking, immunosuppression, or obesity). The primary composite endpoint, which includes venous thromboembolism, invasive mechanical ventilation, major acute cardiovascular events, and mortality within 30 days of randomization, will be assessed according to the intention-to-treat principle. All patients will provide informed consent. A significance level of 5% will be used for all statistical tests. Results Major thrombotic and bleeding outcomes, hospitalizations, and deaths will be centrally adjudicated by an independent clinical events committee blinded to the assigned treatment groups. Conclusion The CARE study will provide relevant and contemporary information about the potential role of thromboprophylaxis in outpatients with COVID-19.
- Published
- 2023
185. Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial
- Author
-
Gilles R. Dagenais, Hyejung Jung, Eva Lonn, Peter M. Bogaty, Mahshid Dehghan, Claes Held, Alvaro Avezum, Petr Jansky, Matyàs Keltai, Lawrence A. Leiter, Patricio Lopez‐Jaramillo, William D. Toff, Jackie Bosch, and Salim Yusuf
- Subjects
antihypertensive agent ,statin ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background It is not clear whether the effects of lipid‐lowering or antihypertensive medications are influenced by adherence to healthy lifestyle factors. We assessed the effects of both drug interventions in subgroups by the number of healthy lifestyle factors in participants in the HOPE‐3 (Heart Outcomes Prevention Evaluation) trial. Methods and Results In this primary prevention trial, 4 healthy lifestyle factors (nonsmoking status, physical activity, optimal body weight, and healthy diet) were recorded in 12 521 participants who were at intermediate risk of cardiovascular disease (CVD) and were randomized to rosuvastatin, candesartan/hydrochlorothiazide, their combination, or matched placebos. Median follow‐up was 5.6 years. The outcome was a composite of CVD events. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression models. Participants with ≥2 healthy lifestyle factors had a lower rate of CVD compared with those with fewer factors (HR: 0.85; 95% CI, 0.73–1.00). Rosuvastatin reduced CVD events in participants with ≥2 healthy lifestyle factors (HR: 0.74; 95% CI, 0.62–0.90) and in participants with
- Published
- 2018
- Full Text
- View/download PDF
186. Risk factors, cardiovascular disease, and mortality in South America: a PURE substudy
- Author
-
Patricio Lopez-Jaramillo, Philip Joseph, Jose P Lopez-Lopez, Fernando Lanas, Alvaro Avezum, Rafael Diaz, Paul A Camacho, Pamela Seron, Gustavo Oliveira, Andres Orlandini, Sumathy Rangarajan, Shofiqul Islam, and Salim Yusuf
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Aims In a multinational South American cohort, we examined variations in CVD incidence and mortality rates between subpopulations stratified by country, by sex and by urban or rural location. We also examined the contributions of 12 modifiable risk factors to CVD development and to death. Methods and results This prospective cohort study included 24 718 participants from 51 urban and 49 rural communities in Argentina, Brazil, Chile, and Colombia. The mean follow-up was 10.3 years. The incidence of CVD and mortality rates were calculated for the overall cohort and in subpopulations. Hazard ratios and population attributable fractions (PAFs) for CVD and for death were examined for 12 common modifiable risk factors, grouped as metabolic (hypertension, diabetes, abdominal obesity, and high non-HDL cholesterol), behavioural (tobacco, alcohol, diet quality, and physical activity), and others (education, household air pollution, strength, and depression). Leading causes of death were CVD (31.1%), cancer (30.6%), and respiratory diseases (8.6%). The incidence of CVD (per 1000 person-years) only modestly varied between countries, with the highest incidence in Brazil (3.86) and the lowest in Argentina (3.07). There was a greater variation in mortality rates (per 1000 person-years) between countries, with the highest in Argentina (5.98) and the lowest in Chile (4.07). Men had a higher incidence of CVD (4.48 vs. 2.60 per 1000 person-years) and a higher mortality rate (6.33 vs. 3.96 per 1000 person-years) compared with women. Deaths were higher in rural compared to urban areas. Approximately 72% of the PAF for CVD and 69% of the PAF for deaths were attributable to 12 modifiable risk factors. For CVD, largest PAFs were due to hypertension (18.7%), abdominal obesity (15.4%), tobacco use (13.5%), low strength (5.6%), and diabetes (5.3%). For death, the largest PAFs were from tobacco use (14.4%), hypertension (12.0%), low education (10.5%), abdominal obesity (9.7%), and diabetes (5.5%). Conclusions Cardiovascular disease, cancer, and respiratory diseases account for over two-thirds of deaths in South America. Men have consistently higher CVD and mortality rates than women. A large proportion of CVD and premature deaths could be averted by controlling metabolic risk factors and tobacco use, which are common leading risk factors for both outcomes in the region.
- Published
- 2022
- Full Text
- View/download PDF
187. Variations in risks from smoking between high-income, middle-income, and low-income countries: an analysis of data from 179 000 participants from 63 countries
- Author
-
Thirunavukkarasu Sathish, Koon K Teo, Philip Britz-McKibbin, Biban Gill, Shofiqul Islam, Guillaume Paré, Sumathy Rangarajan, MyLinh Duong, Fernando Lanas, Patricio Lopez-Jaramillo, Prem K Mony, Lakshmi Pinnaka, Vellappillil Raman Kutty, Andres Orlandini, Alvaro Avezum, Andreas Wielgosz, Paul Poirier, Khalid F Alhabib, Ahmet Temizhan, Jephat Chifamba, Karen Yeates, Iolanthé M Kruger, Rasha Khatib, Rita Yusuf, Annika Rosengren, Katarzyna Zatonska, Romaina Iqbal, Weida Lui, Xinyue Lang, Sidong Li, Bo Hu, Antonio L Dans, Afzal Hussein Yusufali, Ahmad Bahonar, Martin J O’Donnell, Martin McKee, Salim Yusuf, Masira, and 12079642 - Kruger, Iolanthe Marike
- Subjects
Adult ,Male ,Carbon Monoxide ,Nicotine ,Developed Countries ,Respiratory Tract Diseases ,Myocardial Infarction ,General Medicine ,Middle Aged ,Stroke ,Cardiovascular Diseases ,Neoplasms ,Tobacco Smoking ,Humans ,Female ,Prospective Studies ,Developing Countries ,Aged - Abstract
Digital, Background Separate studies suggest that the risks from smoking might vary between high-income (HICs), middle-income (MICs), and low-income (LICs) countries, but this has not yet been systematically examined within a single study using standardised approaches. We examined the variations in risks from smoking across different country income groups and some of their potential reasons. Methods We analysed data from 134 909 participants from 21 countries followed up for a median of 11·3 years in the Prospective Urban Rural Epidemiology (PURE) cohort study; 9711 participants with myocardial infarction and 11 362 controls from 52 countries in the INTERHEART case-control study; and 11 580 participants with stroke and 11 331 controls from 32 countries in the INTERSTROKE case-control study. In PURE, all-cause mortality, major cardiovascular disease, cancers, respiratory diseases, and their composite were the primary outcomes for this analysis. Biochemical verification of urinary total nicotine equivalent was done in a substudy of 1000 participants in PURE. Findings In PURE, the adjusted hazard ratio (HR) for the composite outcome in current smokers (vs never smokers) was higher in HICs (HR 1·87, 95% CI 1·65–2·12) than in MICs (1·41, 1·34–1·49) and LICs (1·35, 1·25–1·46; interaction p, Funding Full funding sources are listed at the end of the paper (see Acknowledgments)., Ciencias Médicas y de la Salud
- Published
- 2022
- Full Text
- View/download PDF
188. Abstract WMP68: Machine Learning Approach In Prediction Of Nasoenteral Tube In Acute Ischemic Stroke
- Author
-
Luiz Dalfior, Michel Machado, Percilia Alves, Pablo Oliveira, Paola da Silva, Geovanna Augusto, Júlian Letícia de Freitas, Luiz Fernando R Oliveira, Igor Terehoff, Nalcer Canedo, Luisa Avezum, Mariana Piva, Mateus Tolentino, Pedro Domingues, Gabriella Dousseau, Isabel Santos, and Maria Sheila G Rocha
- Subjects
Advanced and Specialized Nursing ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine - Abstract
Introduction: Dysphagia occurs in about 20 to 50% of acute stroke patients, and it may persist longer than six months after stroke. Nasoenteral tube feeding (NTF) must be judiciously prescribed to avoid dysphagia complications and, at the same time, prevent its unnecessary usage, which is not free of adverse events. Objective: Our aim was to state independent predictive factors associated with dysphagia and nasoenteral tube feeding. Besides, we aimed to develop a prediction model for nasoenteral tube feeding through a machine learning modeling approach. Methods: This is a prospective cohort study. All consecutive ischemic acute stroke patients were included. All patients had phonoaudiological evaluation for dysphagia screening. Data analyzed included age, sex, Glasgow Coma Scale, NIHSS, Aspects score, Seattle comorbid index, Rankin scale at discharge, TOAST classification for stroke subtypes, presence of major stroke risk factors and data from CT scan of patients. Results: We studied 1101 acute stroke patients. Twenty-eight percent of stroke patients received NTF. They were older (p Conclusions: Dysphagia occurred in one third of cases. Older age, stroke severity, dysarthria, reduced conscious level at onset independently predict the need for nasoenteral tube. The tree decision model is an accurate tool for predicting NTF in acute ischemic stroke patients.
- Published
- 2023
- Full Text
- View/download PDF
189. Abstract TMP12: COVID-19 Increases The Risk Of In-Hospital Acute Stroke Mortality: A Cohort Study
- Author
-
Mariana Piva, Luisa Avezum, Isabel Santos, Gabriella Dousseau, Mateus Tolentino, Nalcer Canedo, Igor Terehoff, Pedro Domingues, Michel Machado, and Maria Sheila G Rocha
- Subjects
Advanced and Specialized Nursing ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine - Abstract
Introduction: Coronavirus disease (COVID-19) infection has an increased risk for neurological complications. Stroke has been associated with COVID-19 in 1-3% of hospitalized patients. Methods: This is a retrospective cohort study of stroke patients admitted in a health center in Brazil. We aimed to investigate whether the exposure to COVID-19 was associated with an increase in acute stroke mortality. The primary outcome was in-hospital mortality. Results: The cohort included 1191 stroke patients (54% male). All strokes were included: Ischemic stroke (81.2%), hemorrhagic stroke (14.9), cerebral venous thrombosis (2.1%) and subarachnoid hemorrhage (1.3%). Stroke associated with COVID-19 represented 5.4% of all patients. Mean age was 64.4 years (SD 0.5) and did not differ between groups. Sex distributions were equal in patients with or without covid-19. The prevalence of stroke type and the TOAST classification were similar in both groups. Mean NIHSS score was 8.7 (SD 6.3) being significantly higher in COVID-19 patients (p=0.036). COVID-19 patients disclosed a higher frequency of previous ischemic heart disease (OR: 3.5 - CI: 1.86-6.46). The frequency of arterial hypertension, diabetes mellitus, tobacco and alcohol use, and atrial fibrillation were similar for both groups. COVID-19 patients disclosed higher odds for in-hospital infection (OR: 4.5; CI: 2.67-7.48). Mortality rate was higher for COVID-19 patients (44.6% against 20.1% in non-Covid-19 group) in all subtypes of stroke. The mortality risk was twofold for COVID-19 stroke patients (CI: 1.62-2.92). Multivariate logistic regression considering mortality as the primary outcome and adjusted for multiple confounders disclosed an adjusted OR of 2.3 for COVID-19 infection (CI: 1.1-4.9) (Figure). Conclusion: In this cohort study, COVID-19 infection was an independent risk factor for mortality in stroke patients, regardless of comorbidities, age, sex and NIHSS.
- Published
- 2023
- Full Text
- View/download PDF
190. Abstract TMP9: Covid-19 Increases The Risk Of Malignant Middle Cerebral Artery Infarction In Acute Stroke
- Author
-
Isabel Santos, Gabriella Dousseau, Luisa Avezum, Mariana Piva, Mateus Tolentino, Igor Terehoff, Pedro Domingues, Nalcer Canedo, Michel Machado, and Maria Sheila G Rocha
- Subjects
Advanced and Specialized Nursing ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine - Abstract
Introduction: Stroke as a presenting feature of COVID-19 infection is being increasingly recognized. The prevalence of malignant middle cerebral artery syndrome (MMC) in acute stroke associated with COVID-19 is yet unknown. Methods: This is a retrospective cohort study of ischemic stroke patients admitted in a health center in Brazil. We investigated the prevalence of malignant middle cerebral artery syndrome in COVID-19 and associated stroke patients. Results: We included 881 ischemic stroke patients (53% male). COVID-19 patients represented 5.3% (N = 47). Mean age was 65.6 years (SD 13.2). COVID-19 patients were significantly younger (mean: 61.4 years; SD: 13.5; p = 0.025) and disclosed a higher odds of previous ischemic heart disease (OR: 4.1 - CI: 1.98-8.16). The frequency of main stroke risk factors was similar for both groups. COVID-19 patients had significantly higher NIHSS (11 points vs 8.2 in non-Covid-19 group - p = 0.006). MMC occurred more frequently in COVID-19 patients (19.5% vs 4.1% of non-covid-19 group - p < 0.001) (Risk ratio: 5.1; CI: 2.63-10.01 - p < 0.001). COVID-19 stroke patients had a longer hospital stay (p < 0.001) and disclosed a higher risk for in-hospital infection (Risk ratio: 4.3 - CI: 2.47-7.53). Rankin scale at 90 days was significantly higher for COVID-19 patients (p Conclusion: In this cohort study, COVID-19 infection was an independent predictor for malignant middle cerebral artery syndrome in ischemic stroke.
- Published
- 2023
- Full Text
- View/download PDF
191. A New Insight into the Rapid Germination Process of Lentil and Cowpea Seeds: High Thiamine and Folate, and Low Α-Galactoside Content
- Author
-
Luiza Avezum, Madode Yann Eméric, Christian Mestres, Nawel Achir, Charlotte Delpech, Morgane Chapron, Olivier Gibert, Loïc Rajjou, and Eric Rondet
- Published
- 2023
- Full Text
- View/download PDF
192. Rivaroxaban to Prevent Major Clinical Outcomes in Non-Hospitalised Patients with COVID-19: The Care – Coalition VIII Randomised Clinical Trial
- Author
-
Alvaro Avezum, Haliton Alves Oliveira Junior, Precil Diego Miranda de Menez Neves, Lucas Bassoli Oliveira Alves, Alexandre Biasi Cavalcanti, Regis Goulart Rosa, Viviane Cordeiro Veiga, Luciano Cesar Pontes Azevedo, Sergio Luiz Zimmermann, Odilson Marques Silvestre, Raphael Cruz Seabra Prudente, Adrian Paulo Morales Kormann, Frederico Rafael Moreira, Icaro Boszczowski, Edgar Brito Sobrinho, Andre Silva Souza, Renato Seligman, Bruno Souza Paolino, Alvaro Razuk, Audes Diogenes Magalhaes Feitosa, Pedro Luiz Monteiro Belmonte, Priscila Freitas Neves Goncalves, Mauro Esteves Hernandes, Ariovaldo Leal Fagundes, Jose Maria Sarmet Esteves, Alexandre Pereira Tognon, John Eikelboom, Otavio Berwanger, Renato Delascio Lopes, Gustavo Bernardes Figueiredo Oliveira, and anon Investigators
- Published
- 2023
- Full Text
- View/download PDF
193. Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: Fundamentação e Desenho do Estudo CARE (CARE – Coalition COVID-19 Brazil VIII)
- Author
-
Oliveira, Gustavo B. F., primary, Neves, Precil Diego M. M., additional, Oliveira, Haliton A., additional, Catarino, Daniela Ghidetti Mangas, additional, Alves, Lucas B. O., additional, Cavalcanti, Alexandre B., additional, Rosa, Regis G., additional, Veiga, Viviane C., additional, Azevedo, Luciano C.P., additional, Berwanger, Otávio, additional, Lopes, Renato D., additional, and Avezum, Álvaro, additional
- Published
- 2023
- Full Text
- View/download PDF
194. A176 ASSOCIATIONS OF ANTIBIOTICS, HORMONAL THERAPIES, ORAL CONTRACEPTIVES, AND LONG-TERM NSAIDS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE PROSPECTIVE URBAN RURAL EPIDEMIOLOGY (PURE) STUDY
- Author
-
Pray, C, primary, Narula, N, additional, Wong, E C, additional, Marshall, J K, additional, Rangarajan, S, additional, Islam, S, additional, Bahonar, A, additional, Alhabib, K F, additional, Kontsevaya, A, additional, Ariffin, F, additional, Co, H U, additional, Al Sharief, W, additional, Szuba, A, additional, Wielgosz, A, additional, Diaz, M L, additional, Yusuf, R, additional, Kruger, L, additional, Soman, B, additional, Li, Y, additional, Wang, C, additional, Yin, L, additional, Erkin, M, additional, Lanas, F, additional, Davletov, K, additional, Rosengren, A, additional, Lopez-Jaramillo, P, additional, Khatib, R, additional, Oguz, A, additional, Iqbal, R, additional, Yeates, K, additional, Avezum, Á, additional, Reinisch, W, additional, Moayyedi, P, additional, and Yusuf, S, additional
- Published
- 2023
- Full Text
- View/download PDF
195. Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network
- Author
-
Nunes, Rafael Amorim Belo, primary, Neves, Precil Diego Miranda de Menezes, additional, da Costa, Leandro Menezes Alves, additional, Bachour, Philip, additional, Cantarelli, Marcelo José de Carvalho, additional, Oliveira, Gustavo Bernardes de Figueiredo, additional, and Avezum Jr., Álvaro, additional
- Published
- 2023
- Full Text
- View/download PDF
196. A burst of fenoterol excretion during the recovery of a weight loss protocol
- Author
-
Cheibub, Ana Maria, primary, Muniz-Santos, Renan, additional, Murgu, Michael, additional, Avezum, Juliana, additional, Abidão-Neto, Bichara, additional, and Cameron, L.C., additional
- Published
- 2023
- Full Text
- View/download PDF
197. Abstract TMP9: Covid-19 Increases The Risk Of Malignant Middle Cerebral Artery Infarction In Acute Stroke
- Author
-
Santos, Isabel, primary, Dousseau, Gabriella, additional, Avezum, Luisa, additional, Piva, Mariana, additional, Tolentino, Mateus, additional, Terehoff, Igor, additional, Domingues, Pedro, additional, Canedo, Nalcer, additional, Machado, Michel, additional, and Rocha, Maria Sheila G, additional
- Published
- 2023
- Full Text
- View/download PDF
198. Abstract WMP68: Machine Learning Approach In Prediction Of Nasoenteral Tube In Acute Ischemic Stroke
- Author
-
Dalfior, Luiz, primary, Machado, Michel, additional, Alves, Percilia, additional, Oliveira, Pablo, additional, da Silva, Paola, additional, Augusto, Geovanna, additional, de Freitas, Júlian Letícia, additional, R Oliveira, Luiz Fernando, additional, Terehoff, Igor, additional, Canedo, Nalcer, additional, Avezum, Luisa, additional, Piva, Mariana, additional, Tolentino, Mateus, additional, Domingues, Pedro, additional, Dousseau, Gabriella, additional, Santos, Isabel, additional, and Rocha, Maria Sheila G, additional
- Published
- 2023
- Full Text
- View/download PDF
199. Abstract TMP12: COVID-19 Increases The Risk Of In-Hospital Acute Stroke Mortality: A Cohort Study
- Author
-
Piva, Mariana, primary, Avezum, Luisa, additional, Santos, Isabel, additional, Dousseau, Gabriella, additional, Tolentino, Mateus, additional, Canedo, Nalcer, additional, Terehoff, Igor, additional, Domingues, Pedro, additional, Machado, Michel, additional, and Rocha, Maria Sheila G, additional
- Published
- 2023
- Full Text
- View/download PDF
200. P856 Associations of antibiotics, hormonal therapies, oral contraceptives, and long-term NSAIDs with Inflammatory Bowel Disease: results from the Prospective Urban Rural Epidemiology (PURE) study
- Author
-
Narula, N, primary, Wong, E C L, additional, Pray, C, additional, Marshall, J K, additional, Rangarajan, S, additional, Islam, S, additional, Bahonar, A, additional, Alhabib, K F, additional, Kontsevaya, A, additional, Ariffin, F, additional, Co, H U, additional, Al Sharief, W, additional, Szuba, A, additional, Wielgosz, A, additional, Diaz, M L, additional, Yusuf, R, additional, Kruger, L, additional, Soman, B, additional, Li, Y, additional, Wang, C, additional, Yin, L, additional, Mirrakhimov, E, additional, Lanas, F, additional, Davletov, K, additional, Rosengren, A, additional, Lopez-Jaramillo, P, additional, Khatib, R, additional, Oguz, A, additional, Iqbal, R, additional, Yeates, K, additional, Avezum, Á, additional, Reinisch, W, additional, Moayyedi, P, additional, and Yusuf, S, additional
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.